Printer Friendly

New Report Pinpoints the Companies Pursuing Metabolomics as their Primary Approach to Drug Repositioning.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c59167) has announced the addition of Decision Resources Inc's new report: Drug Repositioning Strategies for Refueling the Pipeline to their offering.

Drug companies have historically found new indications for their existing drugs serendipitously. Now, however, to refuel product pipelines and improve profit margins, many companies are turning to low-risk strategies such as drug repositioning. Biotech companies such as Dynogen, BrainCells, Gene Logic, and Xenogen are developing technology platforms that aid companies in the development of systematic approaches to this low-risk strategy.

Questions Answered in This Spectrum Report:

* Many new in vivo, ex vivo, in vitro, and in silico drug repositioning approaches are just now emerging. Which approach is likely to have the greatest success in finding unexpected new indications for drugs?

* The pharmaceutical industry is beginning to adopt technologies based on metabolomics--the comprehensive analysis of metabolites. Which companies are pursuing metabolomics as their primary approach to drug repositioning?

* Gene Logic's Phase R Program covers the up-front costs of drug discovery for companies with which it partners. Has Gene Logic's risky strategy been successful in attracting partners? What other partnering strategies are repositioning companies actively pursuing?

* CombinatoRx has developed a high-throughput screening system to evaluate pairs of known compounds for specific diseases. What successes has CombinatoRx had in identifying new combinations of known drugs to be used in specific diseases?

* An essential part of the business strategy for repositioning compounds is ensuring a strong patent estate. What repositioned drugs are most likely to achieve the strongest patent protection?

Scope:

* In vivo technologies: real-time imaging, zebra fish modelling, and multiplexing.

* Ex vivo technologies: kinetic markers and metabolomics.

* In vitro cell-based technologies: genetically engineered cell lines and high-throughput screening.

* In silico technologies: computer simulations and database analyses.

* Repositioning approaches: technology platforms enabling a systematic approach to finding new uses for drugs; use of animal models, cell-based assays, computer simulations, and database analyses pathway-based approaches; the "hypothesis-free" approach.

* Strategies in drug repositioning: trends in repositioning efforts; intellectual property strategies; business models; licensing and collaborative partnerships.

* Outlook: Big Pharma's interest in drug repositioning; the promise of in vivo models; hopes for a powerful technology toolbox; repositioning of branded versus patented drugs.
Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
In Vivo Technologies
Real-Time Imaging in Animal Models
Zebra Fish Disease Models
In Vivo Multiplexing
Ex Vivo Technologies
Kinetic Markers
Metabolomics
Metabolon
Gene Logic
In Vitro Cell-Based Technologies
Bionaut Pharmaceuticals
CombinatoRx
Gene Logic
In Silico Technologies
Arachnova
Inpharmatica
Off-label.com
Sosei
Gene Logic
Repositioning Within a Therapeutic Area
Dynogen
Jenken Biosciences
Vicus Therapeutics
BrainCells
Strategies in Drug Repositioning
Technology Strategies
Intellectual Property Strategies
Business Models
Outlook for Drug Repositioning

Tables
1. Select Technologies for Drug Repositioning
2. Select Companies with Drug Repositioning Technologies or Programs
3. Select Collaborations in Drug Repositioning

Figures
1. Number of FDA-Approved New Molecular Entities (1997-2006) and Total
 Global R&D Spending, PhRMA Members (1997-2005)
2. In Vivo and Ex Vivo Technologies for Drug Repositioning
3. In Vitro, Cell-Based Assays for Drug Repositioning
4. In Silico Technologies for Drug Repositioning

Abbott
ActivX Biosciences
Affymetrix GeneChip
AnalytiCon
Angiotech
Arachnova
Astellas
Asterand
AstraZeneca
Axiom Biosciences
Bayer
Bionaut Pharmaceuticals
BrainCells
Caliper Life Sciences
Celgene
Cephalon
Chronogen
CMIC
CombinatoRx
DanioLabs
Dynogen
Eli Lilly
Euroscreen
Forbes MediTech
Fovea Pharmaceuticals
Gene Logic
GlaxoSmithKline
HenKan Pharmaceutical Company
High Q Foundation
Immune Control
Inpharmatica
Jenken Biosciences
Johnson & Johnson
KineMed
Lundbeck
Melior Discovery
Merck
Metabolon
Millennium
Pharmaceuticals
Mitsubishi Pharma
Novartis
Off-label.com
Organon
Othera Pharmaceuticals
Pharmagene
Phylonix Pharmaceuticals
PhytoHealth
Pfizer
Roche
Sosei
Vastox
Vicus Therapeutics
Xenogen
Znomics
Zygogen


For more information visit http://www.researchandmarkets.com/reports/c59167
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 11, 2007
Words:596
Previous Article:WorkforceLogic Integrates Advisory Services Into Newest HR Software Platform.
Next Article:netForensics Executive to Speak at Two Major Federal Government IT Security Events in June.
Topics:


Related Articles
Country Coach finds new niche with `Rhapsody'.
IFRS: coming to America: what CPAs need to know about the new global GAAP.
Two years and counting: a review of Sarbanes-Oxley section 404 reporting.
BRIEFLY.
Archemix and Merck KGaA Sign Strategic Alliance.
ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis.
New Cheese Tofu Offers Alternative to Meat: Video Report.
Astellas Pharma Announces the Launch of Selective COX-2 Inhibitor Celecox(R) Tablets in Japan.
VIA Pharmaceuticals Receives NASDAQ Deficiency Notice.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters